Study guide

3.4 DSCSA & Drug Supply Chain Integrity

Illinois MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Illinois MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Chapter 2: Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & Illinois Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Chapter 3: Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 Chapter 4: IDFPR, Licensure & Eligibility

4.1 IDFPR Authority & Sources of Illinois Pharmacy Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & Experiential Requirements

5 Chapter 5: Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 Impaired Practitioners & Mandatory Reporting

6 Chapter 6: Technicians, Interns & Supervision

6.1 Technician Registration, Training & Certification 6.2 Supervision, Scope & No Fixed Tech Ratio 6.3 Intern Scope, Delegation & Final Verification

7 Chapter 7: Prescription Authority & Validity

7.1 Who May Prescribe in Illinois 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (720 ILCS 570 + Federal) 7.4 Refills, Partial Fills & E-Prescribing Mandate

8 Chapter 8: Advanced IL Pharmacist Practice

8.1 Collaborative Practice Agreements & Clinical Services 8.2 Immunizations & Vaccine Administration 8.3 Naloxone Access & Opioid Antagonists 8.4 Drug Administration & Therapy Management

9 Chapter 9: Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs

10 Chapter 10: ILPMP & Opioid Public-Health Laws

10.1 Illinois PMP Overview, Reporting & Access 10.2 Mandatory Queries, Designees & Documentation 10.3 Legitimate Medical Purpose & Red Flags

11 Chapter 11: Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Chapter 12: Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Automated Systems & Self-Service Kiosks 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Delivery & Remote Services

13 Chapter 13: Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Illinois Compounding Rules & Beyond-Use Dates

14 Chapter 14: Test-Day Strategy & Final Review

14.1 When Illinois Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

3.4 DSCSA & Drug Supply Chain Integrity

Key Takeaways Explain This Topic AI

The Drug Supply Chain Security Act (DSCSA), Title II of the DQSA of 2013, creates a national interoperable system to trace certain human prescription drugs through the supply chain and combat counterfeit, stolen, and diverted products.

Authorized trading partners include manufacturers, repackagers, wholesale distributors, third-party logistics providers (3PLs), and dispensers (pharmacies); pharmacies may only buy from authorized partners.

Product identifiers (NDC, serial number, lot, expiration) support package-level serialization and verification; transaction documentation (TI and TS; the TH requirement ended November 27, 2023) and multi-year record retention underpin tracing.

Suspect product means reason to believe a product is counterfeit, diverted, stolen, intentionally adulterated, or subject to a fraudulent transaction; illegitimate product means credible evidence of those conditions.

Pharmacies must quarantine suspect product, investigate/verify, and—if illegitimate—notify FDA (Form FDA 3911) and immediate trading partners within 24 hours; Illinois pharmacies remain responsible for IDFPR-compliant acquisition and inventory practices layered on DSCSA.

Last updated: November 2026

3.4 DSCSA & Drug Supply Chain Integrity

Illinois MPJE focus: DSCSA is federal preemptive supply-chain law for covered prescription products. Illinois still licenses pharmacies and wholesale distributors and inspects acquisition records through IDFPR . Exam answers combine authorized trading partners + tracing/verification duties + quarantine/notification with ordinary Illinois permit and recordkeeping expectations.

Legislative Snapshot

The Drug Supply Chain Security Act (DSCSA) is Title II of the Drug Quality and Security Act (DQSA) of 2013 . It replaced a patchwork of state pedigree laws with a national framework to identify and trace certain human prescription drugs as they move from manufacturer to dispenser. Goals include:

  • Electronic, interoperable package-level tracing over a phased implementation
  • Standardized product identifiers on packages and homogeneous cases
  • Verification systems to detect suspect and illegitimate product
  • Restriction of commercial transactions to authorized trading partners

DSCSA does not replace controlled-substance ordering rules (DEA Forms/CSOS) or Illinois pharmacy permit rules; it sits alongside them for supply integrity of finished prescription drugs in commercial distribution.

Authorized Trading Partners

A pharmacy ( dispenser ) may accept ownership of covered prescription products only from an authorized trading partner . Know the cast:

  • Partner Authorization concept
  • Manufacturer FDA establishment registration
  • Repackager FDA registration; affixes product identifiers when repackaging

Wholesale distributor Valid state licensure (shipping/receiving states as applicable) and FDA reporting/database presence

  • 3PL Appropriate licensure/registration for logistics without taking ownership in the classic wholesale sense
  • Dispenser (pharmacy) State pharmacy license (Illinois pharmacy license / IDFPR permit pathway)
  • Wholesale distributor licensing concepts (MPJE-tested)

Wholesale distributors that sell into or from Illinois must hold the required state wholesale licenses for the jurisdictions involved and appear as authorized partners under DSCSA. Pharmacies should:

  • Confirm the wholesaler is licensed before opening an account or accepting ownership
  • Refuse "gray market" or unknown internet sources offering deep discounts on high-demand brands
  • Keep invoices and pedigree/tracing records that show who transferred ownership

Exam rule: Buying "too-good-to-be-true" stock from an unlicensed internet source or a friend with leftover bottles is a DSCSA and IDFPR problem even if the tablets look real.

Serialization and Product Identifiers

Manufacturers and repackagers place a product identifier on each package (and homogeneous case), typically via a 2D Data Matrix barcode plus human-readable elements. Core data elements include:

  • National Drug Code (NDC)
  • Unique serial number for that package
  • Lot number
  • Expiration date

Verification means checking that the product identifier corresponds to what the manufacturer/repackager issued—especially when investigating suspect product, responding to FDA/trading-partner requests, or meeting enhanced verification obligations as interoperability matures. Pharmacists do not need to recite barcode symbology standards, but they must know why serialization exists: package-level authentication and tracing.

Product Tracing Documentation

As ownership changes hands among trading partners, DSCSA requires product tracing information. It is often taught as the 3Ts , but FDA says the requirement to provide and receive transaction history effectively ended on November 27, 2023:

Transaction Information (TI)

Concrete details of the product and the transfer—such as product name, strength, dosage form, NDC, container size and count, lot number, transaction/shipment dates, and seller/buyer names and addresses.

Transaction History (TH)

A statement of prior transactions back to the manufacturer. No longer required: FDA says that beginning November 27, 2023, section 582(k)(1) of the FD&C Act effectively ended the requirement for trading partners to provide and receive it.

Transaction Statement (TS)

A statement affirming that the seller is authorized, received the product from an authorized partner, received required transaction documentation, did not knowingly ship suspect/illegitimate product, and systems are in place as required.

  • Dispenser duties (exam-level)
  • Do not accept product that lacks required tracing information when the transaction is not exempt

Capture and maintain transaction information and statements (or electronic equivalents) for the required retention period—commonly tested as 6 years

Be able to provide tracing information upon request by the appropriate authority or trading partner within required timeframes

  • Continue ordinary Illinois invoice/inventory recordkeeping for IDFPR inspections
  • Common exemptions / carve-outs (recognize, do not over-expand)

DSCSA focuses on commercial distribution of finished prescription drugs. Transactions often discussed as outside ordinary tracing packages include certain patient-specific dispensed product, some intracompany transfers, and other statutory exemptions. When in doubt on a vignette: commercial purchase into pharmacy inventory from a wholesaler is in the system; handing a labeled vial to the patient at counseling is ordinary dispensing, not a wholesale "sale" of tracing stock.

Suspect Versus Illegitimate Product

This distinction is heavily tested.

Status Evidence threshold Core idea

Suspect product Reason to believe the product is counterfeit, diverted, stolen, intentionally adulterated so as to risk serious adverse health consequences or death, subject to a fraudulent transaction, or otherwise unfit for distribution in that serious-risk sense Something looks wrong—act now

  • Illegitimate product Credible evidence establishing those same categories Investigation confirmed the problem
  • Response pathway
  • Quarantine physically and in inventory systems (do not dispense, transfer, or return to saleable stock)

Investigate / verify product identifier and trading-partner information; coordinate with manufacturer/wholesaler as appropriate

If cleared , document and return to inventory only when justified

If illegitimate , notify FDA (commonly via Form FDA 3911 ) and immediate trading partners generally within 24 hours , and arrange proper disposition— never quietly restock confirmed illegitimate product

Reason to believe examples: broken security seals, mismatched lot vs invoice, unknown supplier, patient report that tablets look different with corroborating supply-chain concerns, FDA alert matching your lot.

Credible evidence examples: manufacturer confirmation of counterfeit, law-enforcement confirmation of theft lot, laboratory confirmation of wrong API.

How DSCSA Connects to Adulteration/Misbranding and Illinois Practice

Counterfeit or diverted product is often both a DSCSA illegitimate product problem and an FD&C adulteration/misbranding problem.

Illinois pharmacies must still buy from properly licensed sources under IDFPR rules and maintain invoices for inspections.

Theft/loss of controlled substances still triggers DEA Form 106 and Illinois reporting pathways—DSCSA does not replace CSA security rules taught in Chapter 2.

Central fill and multi-site models must preserve DSCSA documentation responsibilities in written agreements so each site knows who holds tracing records.

  • Practical Illinois Bench Checklist
  • Confirm wholesaler is licensed/authorized before opening an account
  • Match invoices to product received; investigate shortages, overages, and packaging anomalies
  • Train staff to escalate damaged seals, unfamiliar suppliers, and patient "this looks fake" reports
  • Keep electronic/paper tracing records retrievable for 6 years
  • Quarantine first, argue later—never dispense through a red flag to avoid a stock-out conversation

Coordinate DSCSA quarantine with ordinary adulteration instincts: if integrity is in doubt, do not put the product in a patient's hands

Section Checkpoint

DSCSA = national track-and-trace for covered Rx drugs; pharmacies are dispenser trading partners.

Buy only from authorized partners; retain tracing records (commonly 6 years ).

Serialization enables package-level verification .

Suspect = reason to believe → quarantine/investigate; illegitimate = credible evidence → 24-hour FDA/trading-partner notifications and disposition.